As one of the most important academic conferences in the field of gastrointestinal oncology, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) presents a wealth of early-phase drug development data, key registration studies, major research updates, and subgroup analyses every year. These findings represent the latest advancements in the diagnosis and treatment of gastrointestinal cancers. A Phase II multicenter randomized study led by Dr. Zhiqiang Wang from Sun Yat-sen University Cancer Center, which compared the efficacy and safety of albumin-bound docetaxel versus conventional docetaxel in previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma, was selected as an oral abstract (Abstract #333) at this year’s ASCO GI.
